Elevated circulating dipeptidyl peptidase 3 concentrations above 30 ng/mL are associated with a progressively worsening prognosis and increased need for organ support in patients with circulatory failure.
Circulating dipeptidyl peptidase 3 (cDPP3) is a novel biomarker and potential therapeutic target in circulatory failure, with its inhibition by procizumab currently under clinical evaluation.
Circulating dipeptidyl peptidase 3 is a new biomarker linked to circulatory failure prognosis and pathophysiology and is a potential actionable therapeutic target. In this short review intended for the clinician, a question-and-answer format provides key insights on the nature of this biomarker and the therapeutical potential of its targeted inhibition in critically ill patients.
Picod et al. (Thu,) conducted a review in Circulatory failure. Procizumab was evaluated. Elevated circulating dipeptidyl peptidase 3 concentrations above 30 ng/mL are associated with a progressively worsening prognosis and increased need for organ support in patients with circulatory failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: